Novartis Zomaril NDA Filing Awaits More Data On QTc Prolongation
Executive Summary
Novartis is conducting additional trials to determine whether the antipsychotic iloperidone has a dose-dependant QTc prolongation side effect before it files an NDA for the agent.
You may also be interested in...
Novartis Zelnorm Approval: FDA Accepts Overseas History, Active Surveillance
The approval of Novartis' Zelnorm reflects FDA's comfort with an active surveillance program proposed by the company - and the extensive post marketing safety database of the irritable bowel syndrome agent in overseas markets
Novartis/Titan Iloperidone Deal In Doubt In Light Of QTc Prolongation Data
Titan Pharmaceuticals is likely to seek a new partner for iloperidone if Novartis decides to return rights to the schizophrenia drug
Novartis Zelnorm Approval: FDA Accepts Overseas History, Active Surveillance
The approval of Novartis' Zelnorm reflects FDA's comfort with an active surveillance program proposed by the company - and the extensive post marketing safety database of the irritable bowel syndrome agent in overseas markets